mRNA 疫苗减缓黑色素瘤复发。
mRNA Vaccine Slows Melanoma Recurrence.
出版信息
Cancer Discov. 2023 Jun 2;13(6):1278. doi: 10.1158/2159-8290.CD-NB2023-0028.
Abstract
Findings from the phase IIb KEYNOTE-942 trial indicate that the investigational vaccine mRNA-4157/V940 plus pembrolizumab is a potential adjuvant therapy for high-risk melanoma. Following surgery, patients who received the combination experienced a significant reduction in disease recurrence risk, compared with those given just PD-1 inhibitor.
摘要
二期临床试验 KEYNOTE-942 的结果表明，研究性疫苗 mRNA-4157/V940 联合 pembrolizumab 可能成为高危黑色素瘤的辅助治疗药物。与单独使用 PD-1 抑制剂相比，手术后接受联合治疗的患者疾病复发风险显著降低。
Zotero 插件